Enterobiasis differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 13: | Line 13: | ||
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | {| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | ||
! colspan="2" ! style="background:#4479BA; color: #FFFFFF;" |Causes | ! colspan="2" ! style="background:#4479BA; color: #FFFFFF;" |Causes | ||
! style="background:#4479BA; color: #FFFFFF;" | | ! style="background:#4479BA; color: #FFFFFF;" |Signs and symptoms | ||
! style="background:#4479BA; color: #FFFFFF;" |Diagnostic studies | ! style="background:#4479BA; color: #FFFFFF;" |Diagnostic studies | ||
! style="background:#4479BA; color: #FFFFFF;" |Treatment | ! style="background:#4479BA; color: #FFFFFF;" |Treatment | ||
Line 27: | Line 26: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Electrolyte disturbances, increased [[Creatine kinase|CK]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |Electrolyte disturbances, increased [[Creatine kinase|CK]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Relevant history of excessive exercise and lack of water access | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |Relevant history of excessive exercise and lack of water access | ||
|- | |- | ||
| align="center" style="background:#DCDCDC;" | Hemorrhoids(internal or external) | | align="center" style="background:#DCDCDC;" | Hemorrhoids(internal or external) | ||
Line 33: | Line 31: | ||
* Altered mental status | * Altered mental status | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |[[Thrombocytopenia]], [[leukocytosis]], [[leukopenia]], elevated [[Creatinine|Cr]] | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |[[Thrombocytopenia]], [[leukocytosis]], [[leukopenia]], elevated [[Creatinine|Cr]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
|- | |- | ||
Line 41: | Line 38: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |[[Hypercarbia]] (PaCO2) >65 mmHg, [[hyperkalemia]] | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |[[Hypercarbia]] (PaCO2) >65 mmHg, [[hyperkalemia]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of receiving anaesthetic agent | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of receiving anaesthetic agent | ||
|- | |- | ||
| rowspan="4" ! style="background:#4479BA; color: #FFFFFF;" |Infections | | rowspan="4" ! style="background:#4479BA; color: #FFFFFF;" |Infections | ||
Line 49: | Line 45: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Electrolyte disturbances, increased [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]], [[leukocytosis]], [[myoglobinuria]]. | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |Electrolyte disturbances, increased [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]], [[leukocytosis]], [[myoglobinuria]]. | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Relevant history of recent use of anti-psychotics | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |Relevant history of recent use of anti-psychotics | ||
|- | |- | ||
| align="center" style="background:#DCDCDC;" |Candidal | | align="center" style="background:#DCDCDC;" |Candidal | ||
Line 56: | Line 51: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | ||
|- | |- | ||
| align="center" style="background:#DCDCDC;" |Scabies | | align="center" style="background:#DCDCDC;" |Scabies | ||
Line 63: | Line 57: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | ||
|- | |- | ||
| align="center" style="background:#DCDCDC;" |Viral | | align="center" style="background:#DCDCDC;" |Viral | ||
Line 70: | Line 63: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | ||
|- | |- | ||
| rowspan="6" ! style="background:#4479BA; color: #FFFFFF;" |Skin disorders | | rowspan="6" ! style="background:#4479BA; color: #FFFFFF;" |Skin disorders | ||
Line 78: | Line 70: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | ||
|- | |- | ||
| align="center" style="background:#DCDCDC;" |Seborrheic dermatitis | | align="center" style="background:#DCDCDC;" |Seborrheic dermatitis | ||
Line 85: | Line 76: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | ||
|- | |- | ||
| align="center" style="background:#DCDCDC;" |Contact dermatitis | | align="center" style="background:#DCDCDC;" |Contact dermatitis | ||
Line 92: | Line 82: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | ||
|- | |- | ||
| align="center" style="background:#DCDCDC;" |Lichen planus | | align="center" style="background:#DCDCDC;" |Lichen planus | ||
Line 99: | Line 88: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | ||
|- | |- | ||
| align="center" style="background:#DCDCDC;" |Lichen sclerosis | | align="center" style="background:#DCDCDC;" |Lichen sclerosis | ||
Line 106: | Line 94: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | ||
|- | |- | ||
| align="center" style="background:#DCDCDC;" |Perianal carcinoma (Bowen disease) | | align="center" style="background:#DCDCDC;" |Perianal carcinoma (Bowen disease) | ||
Line 113: | Line 100: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | ||
|- | |- | ||
| rowspan="3" ! style="background:#4479BA; color: #FFFFFF;" |Hygiene | | rowspan="3" ! style="background:#4479BA; color: #FFFFFF;" |Hygiene | ||
Line 122: | Line 108: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | ||
|- | |- | ||
| align="center" style="background:#DCDCDC;" |Meticulous cleansing of anal area | | align="center" style="background:#DCDCDC;" |Meticulous cleansing of anal area | ||
Line 129: | Line 114: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | ||
|- | |- | ||
| align="center" style="background:#DCDCDC;" |Skin irritants | | align="center" style="background:#DCDCDC;" |Skin irritants | ||
Line 136: | Line 120: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |Elevated [[Creatine kinase|CK]], [[Lactate dehydrogenase|LDH]], [[Alkaline phosphatase|ALP]], [[Aspartate transaminase|AST]], and [[Alanine transaminase|ALT]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | | style="padding: 5px 5px; background: #F5F5F5;" align="left" |History of recent use of [[Selective serotonin reuptake inhibitor|SSRIs]], [[Serotonin-norepinephrine reuptake inhibitor|SNRIs]] , or [[Monoamine oxidase inhibitor|MAOIs]]. | ||
|} | |} |
Revision as of 14:15, 23 June 2017
Enterobiasis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Enterobiasis differential diagnosis On the Web |
American Roentgen Ray Society Images of Enterobiasis differential diagnosis |
Risk calculators and risk factors for Enterobiasis differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Furqan M M. M.B.B.S[2]
Overview
Enterobiasis must be differentiated from other nematode infections.
Differentiating Enterobiasis from other diseases
The table below summarizes the findings that differentiate enterobiasis from other nematode infections.
References
|